Tesla Shares Rise after Federal Safety Regulators Close Investigation and Aria is a Candidate in Phase II Study
Tesla Motors, Inc. (NASDAQ: TSLA) shares rose on Friday after Federal safety regulators said that they had closed an investigation into whether the design of Tesla Motors’ all-electric car was making it prone to catch fire. This came after the automaker said it would provide more protection to its lithium-ion batteries. The Tesla Model S sedans burst into flames after running over debris two times in the U.S. back in 2013. The drivers were not hurt, but after the second accident, regulators opened their investigation.
On its website, the National Highway Traffic Safety Administration said that the addition of a titanium underbody shield and aluminum deflector plates, along with increased ground clearance, “should reduce both the frequency of underbody strikes and the resultant fire risk.”
Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles and electric vehicle powertrain components. The company also provides services for the development of electric powertrain systems and components, and sells electric vehicle powertrain components to other automotive manufacturers. It markets and sells its vehicles through Tesla stores and galleries, as well as over the Internet.
Get more information on Tesla Motors, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/TSLA
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (:NSCLC) in patients who had previously been treated with Pfizer’s Xalkori (crizotinib). AP26113 is an investigational oral inhibitor of anaplastic lymphoma kinase (ALK), a clinically validated target in certain patients with non-small cell lung cancer, neuroblastomas, sarcomas and lymphomas. In an ongoing Phase 1/2 clinical trial, AP26113 has shown anti-tumor activity in patients with ALK+ NSCLC, including those with active brain metastases. The company said that patients who test positive for the anaplastic lymphoma kinase (ALK+) oncogene will be studied in the ALTA (ALK in Lung Cancer Trial of AP26113) trial. The study will focus on patients who suffer from active brain metastases.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.
Get more information on Ariad Pharmaceuticals Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/ARIA
ABOUT US:
Whether it’s a bull or bear market, TrendingWallStreet has you covered.
TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest stocks trading in the stock market today.
TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at.
TrendingWallStreet.com offers you the best stock tips found on the net. These are sometimes cheap and under-valued stocks in the United States that have the potential to offer gains of 100% or more.
Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
Tags: